ArticleAnnals of surgical oncology2026
ICG-only Sentinel Lymph Node Biopsy in Breast Cancer: A Prospective UK Cohort Demonstrating Consistent Detection Across Patient and Tumour Characteristics-A Follow-on to the INFLUENCE Trial.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Use of indocyanine green fluorescence versus patent blue V dye for sentinel lymph node biopsy in early breast cancer, a randomized controlled trial.Journal of the Egyptian National Cancer Institute · 2026Trial
- ASO Author Reflections: From Feasibility to Implementation: Establishing Indocyanine Green as a Single-Tracer Strategy for Sentinel Lymph Node Biopsy in Breast Cancer.Annals of surgical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundSentinel lymph node biopsy (SLNB) using dual tracer techniques remains the gold standard for axillary staging in early breast cancer. However, reliance on radioisotope mapping introduces logistical complexity, cost, and radiation exposure. Indocyanine green (ICG) fluorescence imaging has emerged as a potential single-tracer alternative, but concerns remain regarding its reliability across heterogeneous patient populations.
methodsA prospective single-centre cohort study was conducted including 300 consecutive SLNB procedures across 292 unique patients using ICG as the sole tracer. The primary endpoints were nodal procedural detection rate and ICG nodal detection rate. Secondary outcomes included: nodal positivity, number of nodes retrieved, operative time, the influence of patient, tumour, and procedural variables. Statistical analysis included linear and logistic regression and correlation analysis.
resultsProcedural nodal detection was achieved in 99.7% (299/300) of procedures, while ICG fluorescent nodal detection was achieved in 97.7% (293/300). Median surgeon-pathologist nodal concordance was 100% (IQR 50-100%), with complete count agreement in 50.7% of procedures. Detection was not influenced by age, body mass index (BMI), tumour size, or procedure type. Operative time increased significantly with BMI (p = 0.0118) and breast-conserving surgery (p < 0.0001).
conclusionsThis large UK prospective series demonstrates that ICG-only fluorescence guidance is safe, efficient, and reproducible, with high procedural and nodal detection rates. Naked-eye visibility of ICG was observed in a subset of cases, further supporting its practicality. Performance was consistent across surgical procedures and patient BMI. These findings support broader adoption of ICG as a single tracer for SLNB.
Indexed as
Identifiers
42527803What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.